Making Gains in HFpEF: An Appraisal of Where We Are Now

In this symposium, we focus on the management of HFpEF and hear from an esteemed faculty on the totality of evidence that places SGLT-2 inhibitors as the only drug class to significantly improve mortality and morbidity in patients with an left ventricular ejection fraction >40%. In addition to hearing about the data which led to changes in the recent ACC guidelines, we’ll also explore the impact of clinical inertia and the remaining challenges in HFpEF management.

This symposium is part of Heart Failure Online 2022, a world-class virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes.

Target Audience

This programme is intended to educate:

  • Heart Failure Specialists
  • General Cardiologists
  • General Practitioners (GPs)
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

Learning Objectives

Upon participation in this programme physicians should be able to:

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF

DISCLOSURES

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

This symposium is supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance. The scientific programme has not been influenced in any way by the sponsors. It is not intended for US or UK based healthcare professionals.

Course summary
Course opens: 
06/27/2022
Course expires: 
06/30/2025
Cost:
£0.00
Rating: 
0

Patient Case: Typical Patient with HFpEF - Dr Shelley Zieroth

SGLT-2 Inhibitors in HFpEF: Totality of Evidence in a Nutshell - Dr Javed Butler

Early Initiation of Foundational Therapy in HF: Why The Urgency? - Prof Carolyn Lam 

Presenters and Panelists: 

Prof Carolyn Lam 

Dr Javed Butler

Dr Shelley Zieroth

Price

Cost:
£0.00
Please login or register to take this course.